Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics

Rational adjustment of surface physicochemical properties of inhalable nanocarriers significantly influences their in vivo fate during pulmonary delivery. Among these, surface hydrophilicity/hydrophobicity has been recognized as a critical factor in the transmucosal process. However, the impacts of surface hydrophilicity/hydrophobicity on the transcellular performance and ultimate therapeutic effects of pulmonary-delivered nanosystems still remain unelucidated. In this study, we developed a series of liposomes with varying surface hydrophilicity to investigate the effect of surface properties on both local and systemic drug delivery. Interestingly, low-hydrophilic liposomes exhibited enhanced systemic absorption, whereas high-hydrophilic liposomes demonstrated prolonged pulmonary residence after inhalation. To validate this principle, we applied two disease models. In a type II diabetes mellitus model, low hydrophilic liposomes loaded with GLP-1 receptor agonists (Liraglutide or Semaglutide) showed excellent systemic drug delivery and hypoglycemic effects. In an OVA-induced allergic asthma model, budesonide-loaded high hydrophilic liposomes significantly alleviated symptoms while reducing dosing frequency. Mechanistic studies further revealed that liposomes with lower surface hydrophilicity could enhance the transcellular transport efficiency of the drug through alveolar epithelial cells, while those with higher surface hydrophilicity prolonged the pulmonary residence of the drug by decreasing alveolar epithelium transportation and the avoidance of macrophage clearance. Lastly, we evaluated the biocompatibility of these liposomes following inhalation. Overall, tuning the surface hydrophilicity/hydrophobicity of inhalable nanocarriers to suit local or systemic delivery goals offers valuable insights for the rational design of advanced pulmonary delivery systems.

Authors

Institutions

Publication Details

Journal
ACS Nano
Published
2025-06-09
DOI
https://doi.org/10.1021/acsnano.5c05745
Citations
5
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
7.59

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics

Sa Li, Yuan Huang, Liyun Xing, Mingjie Ni et al.
5 citations
ACS Nano
Inhalation and Respiratory Drug Delivery
7.59
article

Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics

Sa Li, Yuan Huang, Liyun Xing, Mingjie Ni, Minyi Huang, Xi Liu, Lie Zhang
article en
5 citations

Abstract

Rational adjustment of surface physicochemical properties of inhalable nanocarriers significantly influences their in vivo fate during pulmonary delivery. Among these, surface hydrophilicity/hydrophobicity has been recognized as a critical factor in the transmucosal process. However, the impacts of surface hydrophilicity/hydrophobicity on the transcellular performance and ultimate therapeutic effects of pulmonary-delivered nanosystems still remain unelucidated. In this study, we developed a series of liposomes with varying surface hydrophilicity to investigate the effect of surface properties on both local and systemic drug delivery. Interestingly, low-hydrophilic liposomes exhibited enhanced systemic absorption, whereas high-hydrophilic liposomes demonstrated prolonged pulmonary residence after inhalation. To validate this principle, we applied two disease models. In a type II diabetes mellitus model, low hydrophilic liposomes loaded with GLP-1 receptor agonists (Liraglutide or Semaglutide) showed excellent systemic drug delivery and hypoglycemic effects. In an OVA-induced allergic asthma model, budesonide-loaded high hydrophilic liposomes significantly alleviated symptoms while reducing dosing frequency. Mechanistic studies further revealed that liposomes with lower surface hydrophilicity could enhance the transcellular transport efficiency of the drug through alveolar epithelial cells, while those with higher surface hydrophilicity prolonged the pulmonary residence of the drug by decreasing alveolar epithelium transportation and the avoidance of macrophage clearance. Lastly, we evaluated the biocompatibility of these liposomes following inhalation. Overall, tuning the surface hydrophilicity/hydrophobicity of inhalable nanocarriers to suit local or systemic delivery goals offers valuable insights for the rational design of advanced pulmonary delivery systems.

ACS NanoVol. 19(24)
Sichuan University (CN)
National Natural Science Foundation of China
Openalex Percentile: Top 3%
Inhalation and Respiratory Drug Delivery
7.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.